- 专利标题： Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
-
申请号： US16708082申请日： 2019-12-09
-
公开(公告)号： US11058723B2公开(公告)日： 2021-07-13
- 发明人: Hans G. Klingemann , Laurent H. Boissel , Nathan T. Schomer
- 申请人： NANTKWEST, INC.
- 申请人地址： US CA San Diego
- 专利权人： NANTKWEST, INC.
- 当前专利权人： NANTKWEST, INC.
- 当前专利权人地址： US CA San Diego
- 代理机构： Umberg Zipser LLP
- 代理商 Martin Fessenmaier
- 主分类号： A61K35/17
- IPC分类号： A61K35/17 ; A61P35/00 ; C12N15/62 ; A61P35/02 ; C12N15/85 ; C07K14/705 ; A61K9/00 ; C07K14/82 ; C07K14/55 ; C07K14/725 ; C07K14/54
摘要：
Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.